GlobeNewswire by notified

Clinical ink Relaunches Industry-Leading Partner Program


Will deliver competitive commercial impact via differentiated technological, scientific expertise and operational efficiencies

Horsham, Pennsylvania, USA, Sept. 19, 2022 (GLOBE NEWSWIRE) --

Today Clinical ink, a global life science company, announces the relaunch and expansion of a unique contract research organization (CRO) partnership program. Dedicated to offering our partners, and therefore our joint sponsor customers, a differentiated study experience, the Clinical ink partnership program is rooted in ensuring optimal study design, optimized functional standards, and the implementation of fit-for-purpose technologies to provide successful, best-in-class patient data collection in clinical trials.

Clinical ink has been a leader in providing patient science and patient data collection solutions to CRO Partner for many years, including the majority of the top 10 CRO service providers in addition to many specialized and mid-sized providers. The relaunch of this formal program represents their commitment to the successful deployment of high-quality data solutions in the market, becoming an extension of the expertise and leadership represented within the CROs themselves. 

With hundreds of sponsor relationships and studies deployed, spanning over 85 countries, and a library of over 800+ instruments and assessments, Clinical ink offers CRO partners a trusted, experienced team with which to successfully grow market impact, as well as a robust, end-to-end, patient-centered technology platform. Integral to the Clinical ink partner program is the offering of scientific expertise and support to analyze protocols as well as align comprehensive, compliant, fit-for purpose technology. More, the program offers in-depth training and implementation of technology empowerment to allow for nimble, dynamic clinical study configuration under a subscription license model.  

“We are thrilled to provide this exclusive program to our most valued CRO partners, both current and future,” says Chris Crucitti, Chief Commercial Officer. “Together, we will chart successful growth, powering patient outcomes by providing sponsors not only the most competitive, technologically-advanced eSource, patient data and DCT offering in the market, but also best-in-class operational efficiencies and process optimization to ensure continual, collective advancement.”

About Clinical Ink

Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Telenor etablerer fiberselskap i Norge7.10.2022 08:55:29 CEST | Pressemelding

(Fornebu 07 september 2022) Telenor inngår en transaksjon som skal støtte fremtidige investeringer i Norges telekominfrastruktur. Tidligere i år påbegynte Telenor en prosess for å vurdere etableringen av et eierselskap for passiv fiberinfrastruktur, med en medinvestor i en minoritetsposisjon. Telenor har nå kommet til enighet om å selge 30 prosent av det nye fiberselskapet til et konsortium ledet av det globale investeringsselskapet KKR, som investerer gjennom sin kjerneinfrastrukturstrategi. Konsortiet inkluderer Oslo Pensjonsforsikring som medinvestor. Det nyetablerte selskapet er et datterselskap av Telenor og vil bli en del av det nye forretningsområdet Telenor Infrastruktur. Selskapet vil eie de passive elementene i det norske fibernettet. Dette omfatter omtrent 130.000 kilometer med kabler som leverer tjenester til omtrent 560.000 husstander. Eiendelene vil bli skilt ut fra Telenor Norge før transaksjonen sluttføres. Telenor Norge blir selskapets eneste kunde og alle operasjonell

Telenor establishes fibre company in Norway7.10.2022 08:55:29 CEST | Press release

(Fornebu 7 September 2022) Telenor enters into a transaction supporting future investments in Norway's telecom infrastructure. Earlier this year, Telenor initiated a process of evaluating the establishment of a passive fibre infrastructure ownership company with a minority co-investor. Telenor has now reached an agreement to divest 30 percent of the newly established company, Telenor Fiber AS, in Norway to a consortium led by KKR, investing through its Core Infrastructure strategy. The consortium includes Oslo Pensjonsforsikring as a co-investor. The newly established company is a subsidiary of Telenor and will be a part of the Infrastructure business area. The company will own the passive fibre assets in Norway. This includes 130,000 km of cables, connecting upwards of 560,000 homes. The company’s assets will be transferred from Telenor Norway in a demerger process prior to completion of the transaction. Telenor Norge will be the company’s only customer and all operational processes r

Sampo plc’s share buybacks 06/10/20227.10.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 07/10/2022 at 08:30 am Sampo plc’s share buybacks 06/10/2022 On 06/10/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,28144.90AQEU46,32744.76CEUX9,49144.89TQEX89,90144.82XHELTOTAL160,00044.81 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 11,395,404 Sampo A shares representing 2.14 per cent of the total number of shares in Sampo plc. Details of e

CSC and Intertrust have obtained Regulatory Clearance from the Central Bank of the Bahamas7.10.2022 07:15:00 CEST | Press release

JOINT PRESS RELEASE This is a joint press release by Intertrust N.V. ("Intertrust" or the "Company") and CSC (Netherlands) Holdings B.V. ("CSC" or the "Offeror") in connection with the recommended public offer (the "Offer") by the Offeror for all the issued and outstanding ordinary shares in the capital of Intertrust. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Intertrust. Any offer will be made only by means of the offer memorandum (the "Offer Memorandum") approved by the Dutch Authority for Financial Markets (Stichting Autoriteit Financiële Markten, the "AFM") which was published on 31 March 2022, and subject to the restrictions set forth therein. With reference to the joint press releases of 6 December 2021, 31 March 2022, 30 May 2022, 21 July 2022, and the Intertrust press release of 31 May 2022, the Offer is subject to the satisfaction or waiver of the offer conditions, all in accordance with the terms

Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress6.10.2022 22:01:00 CEST | Press release

Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission, histology data and trajectory modelPresentation on safety data of filgotinib in enriched risk population in rheumatoid arthritis Mechelen, Belgium; 6 October 2022, 22.01 CET, Galapagos NV (Euronext & NASDAQ: GLPG) will present data at the United European Gastroenterology(UEG)Week2022,taking place from8-11 October 2022. Several Galapagos driven presentationswill be showcased, including new post hoc analyses of the SELECTION study, which investigated the safety and efficacy of Jyseleca®(filgotinib), an oral, once-daily, JAK1 preferential inhibitor, in patients with moderately to severely active UC. Dr Walid Abi-Saab, Chief Medical officer of Galapagos said, “We continue to analyze data from the different studies of filgotinib in patients with UC to inform and empower healthcare pro